PRINCETON, N.J., June 13 /PRNewswire-FirstCall/ -- China Biopharma, Inc. provides guidance for fiscal year 2007.
FINANCIAL PROJECTIONS
For fiscal year 2007, the company anticipates total revenues of $10 million, with positive operating income on the bottom line. The potential acquisition of Beijing Tiancheng Haixin Pharmaceutical Co., Ltd. (“BTHP”), a regional distribution company headquartered in Beijing, China, may bring in an additional $3 million to our revenue projections, but has been left out until any potential acquisition can be finalized.
NEW BIOTECH PRODUCTS
The Company expects to add one or two new vaccine products to its product line this year. In addition to its current line of vaccines, the Company is actively engaged in extending its scope to include other biopharmaceutical product lines. One of these is Intravenous Immunoglobulin (IVIG), a plasma product which has proven effective in treating several immune system disorders, including nearly all autoimmune conditions such as CIDP and GBS.
Current vaccine products include human vaccines against Influenza, hemorrhagic fever, and Japanese Encephalitis.
DISTRIBUTION NETWORK
Efforts are underway to form additional distribution partnerships with more global suppliers to distribute their vaccine products throughout this market. The potential acquisition of Beijing Tiancheng Haixin Pharmaceutical Co., Ltd. would add direct distribution channels into 175 hospitals in the region and make a better distribution platform after recent changes in the government policy on all pharmaceutical product distribution.
The company has also entered into a distribution agreement with Takeda Pharmaceutical Company, Ltd. (“Takeda”), the largest pharmaceutical company in Japan. As part of Takeda’s goal to expand sales channels in Asia, China Biopharma has begun distributing Serrapeptase tablets, and the agreement with Takeda calls for China Biopharma to distribute additional drugs as they become available.
MANAGEMENT TEAM
Recently the company added new executives to its management team with extensive experience in pharmaceutical and NASDAQ markets. The company appointed John Murray as the new Chief Financial Officer, and Qiumeng Wang as the new Chief Operation Office of the Company, and both will be instrumental in developing China Biopharma as a leading biotech company in China, and US financial markets.
About China Biopharma Inc.
China Biopharma Inc. is a fast-growing biopharmaceutical company based in China. Through its operating subsidiaries, the Company develops and distributes biopharmaceutical and pharmaceutical products throughout the world’s most populated country, China. Products include human vaccines against influenza, hemorrhagic fever, and Japanese Encephalitis. Leveraging its investment and ownership of local Chinese biopharmaceutical companies, and partnerships with international biopharmaceutical companies, China Biopharma is building a highly-competitive platform for growth in China as well as new markets, including the U.S. and Europe. For more information, visit its website at http://www.chinabiopharma.net.
CONTACT: China Biopharma, Inc. Attn.: George Ji Tel: +1 (609) 651-8588 ir@chinabiopharma.netwww.chinabiopharma.net
China Biopharma, Inc.
CONTACT: George Ji of China Biopharma, Inc., +1-609-651-8588,ir@chinabiopharma.net
Web site: http://www.chinabiopharma.net/
